Editas Medicine Statistics
Editas Medicine (8EM) Stock Statistics & Valuation Metrics
Total Valuation
Editas Medicine has a market cap or net worth of CHF 323.51M. The enterprise value is CHF 246.12M.
- Market Cap
- CHF 323.51M
- Enterprise Value
- CHF 246.12M
Share Statistics
Editas Medicine has 153,580,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 153,580,030
- Owned by Insiders
- 0.29%
- Owned by Institutions
- 25.08%
Financial Efficiency
Editas Medicine’s return on equity (ROE) is -5.87 and return on invested capital (ROIC) is -65.65%.
- Return on Equity (ROE)
- -5.87
- Return on Assets (ROA)
- -0.86
- Return on Invested Capital (ROIC)
- -65.65%
- Return on Capital Employed (ROCE)
- -0.71
- Revenue Per Employee
- 465.75K
- Profits Per Employee
- -1.84M
- Employee Count
- 87
- Asset Turnover
- 0.22
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Editas Medicine is -4.45. Editas Medicine’s PEG ratio is -0.03.
- PE Ratio
- -4.45
- PS Ratio
- 10.70
- PB Ratio
- 5.00
- Price to FCF
- -3.82
- Price to Operating Cash Flow
- -3.83
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Editas Medicine had revenue of 40.52M and earned -160.06M in profits. Earnings per share was -1.80.
- Revenue
- 40.52M
- Gross Profit
- 40.52M
- Operating Income
- -99.34M
- Pretax Income
- -160.06M
- Net Income
- -160.06M
- EBITDA
- -148.61M
- Earnings Per Share (EPS)
- -1.80
Cash Flow
In the last 12 months, operating cash flow was -110.21M and capital expenditures -258,000, giving a free cash flow of -110.46M billion.
- Operating Cash Flow
- -110.21M
- Free Cash Flow
- -110.46M
- Free Cash Flow per Share
- -0.72
Dividends & Yields
Editas Medicine pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -28.70%
- Earnings Yield
- -17.19%
Stock Price Statistics
- Beta
- 0.83
- 52-Week Price Change
- -29.36%
- 50-Day Moving Average
- 2.17
- 200-Day Moving Average
- 2.34
- Relative Strength Index (RSI)
- 46.18
- Average Volume (3m)
- ―
Important Dates
Editas Medicine upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Editas Medicine as a current ratio of 3.54, with Debt / Equity ratio of 281.10%
- Current Ratio
- 3.54
- Quick Ratio
- 3.54
- Debt to Market Cap
- 0.36
- Net Debt to EBITDA
- 0.47
- Interest Coverage Ratio
- -16.10
Taxes
In the past 12 months, Editas Medicine has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Editas Medicine EV to EBITDA ratio is -6.78, with an EV/FCF ratio of -2.71.
- EV to Sales
- 8.28
- EV to EBITDA
- -6.78
- EV to Free Cash Flow
- -2.71
- EV to Operating Cash Flow
- -2.73
Balance Sheet
Editas Medicine has CHF 190.20M in cash and marketable securities with CHF 13.94M in debt, giving a net cash position of CHF 176.26M billion.
- Cash & Marketable Securities
- CHF 190.20M
- Total Debt
- CHF 13.94M
- Net Cash
- CHF 176.26M
- Net Cash Per Share
- CHF 1.15
- Tangible Book Value Per Share
- CHF 0.55
Margins
Gross margin is 98.78%, with operating margin of -145.89%, and net profit margin of -183.02%.
- Gross Margin
- 98.78%
- Operating Margin
- -145.89%
- Pretax Margin
- -183.02%
- Net Profit Margin
- -183.02%
- EBITDA Margin
- -122.22%
- EBIT Margin
- -126.53%
Analyst Forecast
The average price target for Editas Medicine is CHF 4.26, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CHF 4.26
- Price Target Upside
- 106.70% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 20.83%
- EPS Growth Forecast
- 73.89%
Scores
- Smart Score
- 7
- AI Score
- ―
